UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 91

Sortiert nach

Docetaxel Activity in the Era of Life-prolonging Hormonal Therapies for Metastatic Castration-resistant Prostate Cancer

European urology, 2016-09, Vol.70 (3), p.410-412

2016

Volltextzugriff (PDF)

Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)

The Prostate, 2018-09, Vol.78 (12), p.889-895

2018

Volltextzugriff (PDF)

Cell-Free DNA: Unveiling the Future of Cancer Diagnostics and Monitoring

Cancers, 2024-02, Vol.16 (3), p.662

2024

Volltextzugriff (PDF)

Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases

Prostate cancer and prostatic diseases, 2021-06, Vol.24 (2), p.341-348

2021

Volltextzugriff (PDF)

Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry

Prostate cancer and prostatic diseases, 2019-09, Vol.22 (3), p.420-427

2019

Volltextzugriff (PDF)

The third line of treatment for metastatic prostate cancer patients: Option or strategy?

Critical reviews in oncology/hematology, 2015-09, Vol.95 (3), p.265-271

2015

Volltextzugriff (PDF)

Circulating Cell-Free DNA in Renal Cell Carcinoma: The New Era of Precision Medicine

Cancers, 2022-09, Vol.14 (18), p.4359

2022

Volltextzugriff (PDF)

Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

Journal of translational medicine, 2023-02, Vol.21 (1), p.75-75, Article 75

2023

Volltextzugriff (PDF)

Tumor fraction in cell-free DNA as a biomarker in prostate cancer

JCI insight, 2018-11, Vol.3 (21)

2018

Volltextzugriff (PDF)

Impact of Different Selection Approaches for Identifying Lynch Syndrome-Related Colorectal Cancer Patients: Unity Is Strength

Frontiers in oncology, 2022-02, Vol.12, p.827822-827822

2022

Volltextzugriff (PDF)

The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study

Translational oncology, 2021-02, Vol.14 (2), p.100973-100973, Article 100973

2021

Volltextzugriff (PDF)

The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis

Therapeutic advances in medical oncology, 2022, Vol.14, p.175883592211101-17588359221110162

2022

Volltextzugriff (PDF)

Immunity Feedback and Clinical Outcome in Colon Cancer Patients Undergoing Chemoimmunotherapy with Gemcitabine + FOLFOX followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Aldesleukin (GOLFIG-1 Trial)

Clinical cancer research, 2008-07, Vol.14 (13), p.4192-4199

2008

Volltextzugriff (PDF)

Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

Therapeutic advances in medical oncology, 2023-01, Vol.15, p.17588359231156147-17588359231156147

2023

Volltextzugriff (PDF)

Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab

The Journal of the American Dental Association (1939), 2011-05, Vol.142 (5), p.506

2011

Volltextzugriff (PDF)

Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer

Cancers, 2021-08, Vol.13 (16), p.4055

2021

Volltextzugriff (PDF)

CEA and CA19.9 as Early Predictors of Progression in Advanced/Metastatic Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy and Bevacizumab

Cancer investigation, 2012-01, Vol.30 (1), p.65-71

2012

Volltextzugriff (PDF)

Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer

Clinical genitourinary cancer, 2018-04, Vol.16 (2), p.130-134

2018

Volltextzugriff (PDF)

Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer

International journal of clinical oncology, 2011-06, Vol.16 (3), p.264-269

2011

Volltextzugriff (PDF)

Tolerability of single‐agent sorafenib in the treatment of elderly patients with hepatocellular carcinoma (HCC)

Hepatology (Baltimore, Md.), 2014-08, Vol.60 (2), p.764-765

2014

Volltextzugriff (PDF)

Doxycycline or minocycline may be a viable treatment option against SARS-CoV-2

Medical hypotheses, 2020-11, Vol.144, p.110054-110054, Article 110054

2020

Volltextzugriff (PDF)

Breast cancer in patients with Lynch syndrome: A single institution retrospective analysis

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e22549-e22549

2023

Volltextzugriff (PDF)

Hyperprogressive disease in advanced cancer patients treated with nivolumab: a case series study

Anti-cancer drugs, 2020-02, Vol.31 (2), p.190

2020

Volltextzugriff (PDF)

1 – 25 von 91

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(86)
Mit Volltextzugriff
(88)

Publikationsform

Artikel
(89)
Berichte
(2)

Sprache

Englisch
(91)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(66)
Science & Technology
(66)
Oncology
(55)
Humans
(49)
Male
(44)
Aged
(33)
Middle Aged
(29)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(27)
Aged, 80 And Over
(22)
Female
(22)
Prostate Cancer
(20)
Prostatic Neoplasms, Castration-Resistant - Drug Therapy
(17)
Chemotherapy
(16)
Metastasis
(15)
Treatment Outcome
(15)
Adult
(14)
Pharmacology & Pharmacy
(14)
Neoplasm Metastasis
(13)
Prognosis
(12)
Docetaxel
(11)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Docetaxel Activity in the Era of Life-prolonging Hormonal Therapies for Metastatic Castration-resistant Prostate Cancer

Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)

Cell-Free DNA: Unveiling the Future of Cancer Diagnostics and Monitoring

Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases

Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry

The third line of treatment for metastatic prostate cancer patients: Option or strategy?

Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study

Circulating Cell-Free DNA in Renal Cell Carcinoma: The New Era of Precision Medicine

Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

Tumor fraction in cell-free DNA as a biomarker in prostate cancer

Impact of Different Selection Approaches for Identifying Lynch Syndrome-Related Colorectal Cancer Patients: Unity Is Strength

GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up

The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study

The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis

Immunity Feedback and Clinical Outcome in Colon Cancer Patients Undergoing Chemoimmunotherapy with Gemcitabine + FOLFOX followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Aldesleukin (GOLFIG-1 Trial)

Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab

Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer

CEA and CA19.9 as Early Predictors of Progression in Advanced/Metastatic Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy and Bevacizumab

Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer

Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer

Tolerability of single‐agent sorafenib in the treatment of elderly patients with hepatocellular carcinoma (HCC)

Doxycycline or minocycline may be a viable treatment option against SARS-CoV-2

Breast cancer in patients with Lynch syndrome: A single institution retrospective analysis

Hyperprogressive disease in advanced cancer patients treated with nivolumab: a case series study

Suchergebnisse filtern